{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:41:55Z","timestamp":1793378515255,"version":"4.5.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Prostate cancer (PCa) detection is usually achieved by PSA measurement and, if indicated, further diagnostics. The recent EAU guidelines recommend a first PSA test at the age of 50\u00a0years, if no family history of PCa or BRCA2 mutation exists. However, some men might harbor significant PCa at younger age; thus we evaluated the histopathological results of men treated with radical prostatectomy (RP) in their 40\u00a0s at our institution.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>We relied on the data of all patients who underwent RP in our institution between 1992 and 2020 and were younger than 50\u00a0years at the time of surgery. The histopathological results are descriptively presented. Moreover, we tested the effect of a positive family history on the descriptive results.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 1225 patients younger than 50\u00a0years underwent RP at our institution. Median age was 47\u00a0years. Most patients showed favorable histopathological characteristics. However, 20% of patients had extraprostatic disease (\u2265\u2009pT3a), 15% had ISUP Gleason grade group\u2009\u2265\u20093, and 7% had positive lymph nodes (pN1). Patients with a known positive family history did not have a higher rate of adverse disease as their counterparts with a negative family history.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Our data show that the majority of patients who were diagnosed with PCa at a very young age had favorable histopathological RP characteristics. However, a non-negligible proportion of patients already showed locally advanced disease and would have probably benefited from earlier PCa detection. This should be kept in mind when PCa screening recommendations are proposed.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00345-023-04287-1","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T14:20:29Z","timestamp":1674138029000},"page":"421-425","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Histopathological results of radical prostatectomy specimen of men younger than 50\u00a0years of age at the time of surgery: possible implications for prostate cancer screening programs?"],"prefix":"10.1007","volume":"41","author":[{"given":"Gisa","family":"Mehring","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Heinzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Steuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randi M.","family":"Pose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imke","family":"Thederan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bud\u00e4us","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Salomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Haese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Michl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartwig","family":"Huland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Graefen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7091-2716","authenticated-orcid":false,"given":"Hendrik","family":"Isbarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"issue":"8","key":"4287_CR1","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/S1470-2045(10)70146-7","volume":"11","author":"J Hugosson","year":"2010","unstructured":"Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P et al (2010) Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11(8):725\u2013732","journal-title":"Lancet Oncol"},{"issue":"9959","key":"4287_CR2","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","volume":"384","author":"FH Schroder","year":"2014","unstructured":"Schroder FH, Hugosson J, Roobol MJ, Tammela TLJ, Zappa M, Nelen V et al (2014) Screening and prostate cancer mortality: results of the European randomised study of screening for prostate cancer (ERSPC) at 13 years of follow-up. Lancet 384(9959):2027\u20132035","journal-title":"Lancet"},{"issue":"18","key":"4287_CR3","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1056\/NEJMc1515131","volume":"374","author":"JE Shoag","year":"2016","unstructured":"Shoag JE, Mittal S, Hu JC (2016) Reevaluating PSA testing rates in the PLCO trial. New Engl J Med 374(18):1795\u20131796","journal-title":"New Engl J Med"},{"issue":"1","key":"4287_CR4","first-page":"78","volume":"122","author":"BA Mahal","year":"2016","unstructured":"Mahal BA, Aizer AA, Efstathiou JA, Nguyen PL (2016) Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer. Cancer-Am Cancer Soc 122(1):78\u201383","journal-title":"Cancer-Am Cancer Soc"},{"issue":"1","key":"4287_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.eururo.2016.03.026","volume":"71","author":"S Carlsson","year":"2017","unstructured":"Carlsson S, Assel M, Ulmert D, Gerdtsson A, Hugosson J, Vickers A et al (2017) Screening for prostate cancer starting at age 50\u201354 years a population-based cohort study. Eur Urol 71(1):46\u201352","journal-title":"Eur Urol"},{"issue":"2","key":"4287_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 79(2):243\u201362","journal-title":"Eur Urol"},{"issue":"6","key":"4287_CR7","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMc1807507","volume":"379","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, Emberton M, Moore CM (2018) MRI-targeted biopsy for prostate-cancer diagnosis reply. New Engl J Med 379(6):589\u2013590","journal-title":"New Engl J Med"},{"issue":"6","key":"4287_CR8","first-page":"1210","volume":"117","author":"H Lilja","year":"2011","unstructured":"Lilja H, Cronin AM, Dahlin A, Manjer J, Nilsson PM, Eastham JA et al (2011) Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer-Am Cancer Soc 117(6):1210\u20131219","journal-title":"Cancer-Am Cancer Soc"},{"issue":"11","key":"4287_CR9","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1002\/ijc.33940","volume":"150","author":"C Arsov","year":"2022","unstructured":"Arsov C, Albers P, Herkommer K, Gschwend J, Imkamp F, Peters I et al (2022) A randomized trial of risk-adapted screening for prostate cancer in young men-results of the first screening round of the PROBASE trial. Int J Cancer 150(11):1861\u20131869","journal-title":"Int J Cancer"},{"issue":"1","key":"4287_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/bju.12407","volume":"114","author":"A Becker","year":"2014","unstructured":"Becker A, Tennstedt P, Hansen J, Trinh QD, Kluth L, Atassi N et al (2014) Functional and oncological outcomes of patients aged < 50 years treated with radical prostatectomy for localised prostate cancer in a European population. BJU Int 114(1):38\u201345","journal-title":"BJU Int"},{"key":"4287_CR11","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1111\/iju.14990","volume":"29","author":"T Sasaki","year":"2022","unstructured":"Sasaki T, Matsumoto R, Higashi S, Kato M, Masui S, Yoshio Y et al (2022) Impact of family history on clinicopathological variables and disease progression in Japanese prostate cancer patients undergoing robotic-assisted radical prostatectomy. Int J Urol 29:1339\u20131346","journal-title":"Int J Urol"},{"issue":"4","key":"4287_CR12","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S0022-5347(18)35794-X","volume":"173","author":"KL Lee","year":"2005","unstructured":"Lee KL, Marotte JB, Ferrari M, McNeal JE, Brooks JD, Presti JC (2005) Positive family history of prostate cancer is not associated with worse outcomes after radical prostatectomy. J Urol. 173(4):453","journal-title":"J Urol."}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-023-04287-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-023-04287-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-023-04287-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T06:06:17Z","timestamp":1679897177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-023-04287-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":12,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["4287"],"URL":"https:\/\/doi.org\/10.1007\/s00345-023-04287-1","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,19]]},"assertion":[{"value":"5 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}